Industry & Business

Neuromod raises €5.5m to fund clinical trials for device in the US

 Breaking News
  • Grand Canal Innovation District Planned For Dublin A far-reaching plan for the creation of the Grand Canal Innovation District in Dublin has been launched. The proposal from Trinity College Dublin is modelled on innovation districts in cities such as Boston, Toronto, Rotterdam and Barcelona. It will significantly strengthen Ireland’s competitive advantage when developing new indigenous companies or competing for foreign direct investment. [...]...
  • Heiton Buckley Unveils Newly Refurbished Mayo Branch Heiton Buckley, Ireland’s leading supplier of doors, floors, bathrooms, garden, plumbing and heating products, has officially unveiled its newly refurbished branch in Castlebar, County Mayo . GAA star, Andy Moran, CEO of Grafton Merchanting ROI, Patrick Atkinson, Heiton Buckley Castlebar Branch Manager, Mick Kane, and longtime customer Mick Duane officially cut the ribbon and kicked [...]...
  • Export Sales by Enterprise Ireland Client Companies Hit New Record Enterprise Ireland, the state agency responsible for helping Irish companies export to international markets, has announced that its clients recorded export sales of €22.71 billion in 2017, representing a 7 per cent increase on 2016. This is the highest level of export sales recorded in the history of the agency and the eighth-consecutive year of [...]...
  • BAM Wins €25 Million Contract to Build New Cheese Factory in Cork TINE Ireland, a subsidiary of the Norwegian dairy co-operative TINE, has awarded the construction of a new Jarlsberg® cheese production facility and administration building at Mogeely, County Cork, to BAM Ireland. The contract value is more than €25 million. TINE is Norway’s largest producer, distributor and exporter of dairy products with 11,400 members (owners) and [...]...
  • HBAN Scoops Major European Business Angel Network Award HBAN (Halo Business Angel Network), the all-island organisation responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland and InterTradeIreland, was crowned Globally Networked Organisation 2018 at the recent EBAN (European Business Angel Network) Awards Ceremony held in Sofia, Bulgaria. HBAN was awarded the prominent European accolade in recognition of the significant [...]...

Neuromod raises €5.5m to fund clinical trials for device in the US

Neuromod raises €5.5m to fund clinical trials for device in the US
September 29
08:48 2015

Irish company Neuromod has raised €5.5 million to fund clinical trials in the US for a device that targets millions of people suffering from chronic tinnitus.

Tinnitus, often described as a ringing or buzzing in the ears, affects as many and there are very limited treatment options currently available.

Neuromod, a company spun out of NUI Maynooth, has raised the money in its first institutional fundraising from lrish life sciences venture capital group Fountain Healthcare Partners. Until now, the company had raised around €2 million in a series of private investments, with support from Enterprise Ireland.

The medical device group uses neuromodulation – targeting he nervous system with electrical stimulation to control symptoms or relieve pain – effectively to “retrain the brain”.

Tinnitus is caused when hair cells or nerve fibres in the inner ears are damaged. Recent scientific research argues that the phantom noise emanates from the brain trying to “compensate” by “turning up the volume”, as Jennifer Melcher of the Massachusetts Eye and Ear Infirmary put it in a recent piece on the condition in The Scientist Magazine.


Neuromod’s Mutebutton device uses stimulation through the ear via headphones and sensory stimulation with a pad that clips on to the tip of the tongue.

The Mutebutton, which has been trailed successfully in 50 patients, has already been approved for sale in Europe and is available in the Irish market. However, the company has decided to prioritise regulatory approval in the key US market ahead of any broader commercialisation in Europe.

“As a small innovative venture capital -backed company, our intention is to focus our resources on strategic goals,” says Neuromod founder and chief executive Ross O’Neill,The company is targeting commercialisation internationally in 2018. Aside from US Trials, Mr O’Neill said the company will also use the funds raised to work on fine-tuning treatment dose and also to conduct more work in which subgroups of patients with tinnitus will respond more effectively to its therapy.

Tinnitus affects as many as one in five people. Existing drug therapies are relevant only for acute tinnitus addressed in the first 90 days. Thereafter, as the condition becomes chronic, other therapies are required. But, until recently, tinnitus has struggled to get research dollars. As of now, apart from Neuromod, there are only three companies investigating approaches to relieve chronic tinnitus.

Fountain Healthcare Partners managing partner Manus Rogan says the Neuromod deal is one of the first VC investments in the area of tinnitus. The company has already invested in another neuromodulation -based group, Mainstay Medical, which is targeting chronic lower back pain with an implantable device

“This represents an intersection of two hot areas which we as a firm have a keen interest in,” Said Dr Rogan.

He said a recently acquired US patent, alongside the CE mark for European commercialisation and strong results from its 50-patient trial makes Neuromod a strong investment candidate which now has the capital to move forward.

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4